FIB-4 score as predictor of COVID-19-related severity in hospitalized patients

FIB-4 score as predictor of COVID-19-related severity in hospitalized patients

To determine the impact of liver fibrosis on the prognosis of COVID and the liver injury associated with the infection. Retrospective multicenter study including 575 patients requiring admission for COVID-19 between January and June 2020. FIB-4 was calculated within 6 months prior to infection and a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Revista española de enfermedades digestivas 2024-09, Vol.116 (9), p.465
Hauptverfasser: Lucena Valera, Ana, Aller Dela Fuente, Rocío, Sánchez Torrijos, Yolanda, Romero Gómez, Manuel, Ampuero Herrojo, Javier
Format: Artikel
Sprache:eng ; spa
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 9
container_start_page 465
container_title Revista española de enfermedades digestivas
container_volume 116
creator Lucena Valera, Ana
Aller Dela Fuente, Rocío
Sánchez Torrijos, Yolanda
Romero Gómez, Manuel
Ampuero Herrojo, Javier
description To determine the impact of liver fibrosis on the prognosis of COVID and the liver injury associated with the infection. Retrospective multicenter study including 575 patients requiring admission for COVID-19 between January and June 2020. FIB-4 was calculated within 6 months prior to infection and at 6 months post-infection. Baseline FIB-4 was increased in patients who died (1.91±0.95 vs. 1.43±0.85; p
doi_str_mv 10.17235/reed.2024.9811/2023
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_3057075037</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A812486018</galeid><sourcerecordid>A812486018</sourcerecordid><originalsourceid>FETCH-LOGICAL-c330t-91a5ed37413ff998a80734bef2760e1586d2fbd53739e194bc07225f5459f61c3</originalsourceid><addsrcrecordid>eNptkU1r3DAQhnVoaJJt_kEohkDpxZvRlyUf023TLoTm0uYqtPKoq-K1HEkbSH997WwCDZQ5zKB53gHxEHJOYUkV4_IyIXZLBkwsW03p5TTxN-SEUg41UNDH5DTn3wCCN5K9Jcdcq0aBkCfk-_X6Uy2q7GLCyuZqTNgFV2Kqoq9Wt3frzzVt64S9LdhVGR8whfJYhaHaxjyGYvvwZ1qMtgQcSn5HjrztM5499wX5ef3lx-pbfXP7db26uqkd51DqllqJHVeCcu_bVlsNiosNeqYaQCp10zG_6SRXvEXaio0DxZj0UsjWN9TxBfl4uDumeL_HXMwuZId9bweM-2w4SAVKwnRgQS4O6C_bowmDjyVZN-PmSlMmdANUT9TyP9RUHe6CiwP6ML2_Cnz4J7BF25dtjv2-hDjk16A4gC7FnBN6M6aws-nRUDBP9sxsz8z2zGxvnvgUe__8w_1mN61fQi_q-F_JcpPb</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3057075037</pqid></control><display><type>article</type><title>FIB-4 score as predictor of COVID-19-related severity in hospitalized patients</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Lucena Valera, Ana ; Aller Dela Fuente, Rocío ; Sánchez Torrijos, Yolanda ; Romero Gómez, Manuel ; Ampuero Herrojo, Javier</creator><creatorcontrib>Lucena Valera, Ana ; Aller Dela Fuente, Rocío ; Sánchez Torrijos, Yolanda ; Romero Gómez, Manuel ; Ampuero Herrojo, Javier</creatorcontrib><description><![CDATA[To determine the impact of liver fibrosis on the prognosis of COVID and the liver injury associated with the infection. Retrospective multicenter study including 575 patients requiring admission for COVID-19 between January and June 2020. FIB-4 was calculated within 6 months prior to infection and at 6 months post-infection. Baseline FIB-4 was increased in patients who died (1.91±0.95 vs. 1.43±0.85; p<0.001). In addition, the 17.1% (32/187) of patients with baseline FIB-4<1.45 died versus 52.9% (9/17) if FIB-4>3.25 (p<0.001). In the adjusted multivariate analysis, baseline FIB-4 (OR 1.61 (95%CI 1.19-2.18); p=0.002) was independently associated with mortality. Parameters associated with liver injury, including AST (28±10 vs. 45±56IU/L; p<0.001) and ALT (20±12 vs. 38±48IU/L; p<0.001) were significantly higher at admission compared to baseline. Also, FIB-4 was increased from baseline to the time of admission (1.53±0.88 vs. 2.55±1.91; p<0.001), and up to 6.9% (10/145) of patients with FIB-4<1.45 at admission died versus 47.5% if FIB-4>3.25 (58/122) (p<0.001). In the adjusted multivariate analysis, FIB-4 at admission (OR 1.14 (95%CI 1.03-1.27); p=0.015) was independently associated with mortality. Also, AST (42±38 vs. 22±17IU/L; p<0.001) and ALT (40±50 vs. 20±19 IU/L; p<0.001) were significantly reduced at 6 months after the resolution of infection. Accordingly, FIB-4 decreased significantly (2.12±1.25 vs. 1.32±0.57; p<0.001) six months after the infection. Increased FIB-4, either at baseline or at the time of admission, was related to the severity and mortality related to SARS-CoV-2 infection. However, the liver damage expressed by elevated transaminases and FIB-4 was reversible in most of patients.]]></description><identifier>ISSN: 1130-0108</identifier><identifier>DOI: 10.17235/reed.2024.9811/2023</identifier><identifier>PMID: 38767045</identifier><language>eng ; spa</language><publisher>Spain: Sociedad Espanola de Patologia Digestivas</publisher><ispartof>Revista española de enfermedades digestivas, 2024-09, Vol.116 (9), p.465</ispartof><rights>COPYRIGHT 2024 Sociedad Espanola de Patologia Digestivas</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c330t-91a5ed37413ff998a80734bef2760e1586d2fbd53739e194bc07225f5459f61c3</cites><orcidid>0000-0001-8494-8947 ; 0000-0003-1460-545X ; 0000-0002-8332-2122</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38767045$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lucena Valera, Ana</creatorcontrib><creatorcontrib>Aller Dela Fuente, Rocío</creatorcontrib><creatorcontrib>Sánchez Torrijos, Yolanda</creatorcontrib><creatorcontrib>Romero Gómez, Manuel</creatorcontrib><creatorcontrib>Ampuero Herrojo, Javier</creatorcontrib><title>FIB-4 score as predictor of COVID-19-related severity in hospitalized patients</title><title>Revista española de enfermedades digestivas</title><addtitle>Rev Esp Enferm Dig</addtitle><description><![CDATA[To determine the impact of liver fibrosis on the prognosis of COVID and the liver injury associated with the infection. Retrospective multicenter study including 575 patients requiring admission for COVID-19 between January and June 2020. FIB-4 was calculated within 6 months prior to infection and at 6 months post-infection. Baseline FIB-4 was increased in patients who died (1.91±0.95 vs. 1.43±0.85; p<0.001). In addition, the 17.1% (32/187) of patients with baseline FIB-4<1.45 died versus 52.9% (9/17) if FIB-4>3.25 (p<0.001). In the adjusted multivariate analysis, baseline FIB-4 (OR 1.61 (95%CI 1.19-2.18); p=0.002) was independently associated with mortality. Parameters associated with liver injury, including AST (28±10 vs. 45±56IU/L; p<0.001) and ALT (20±12 vs. 38±48IU/L; p<0.001) were significantly higher at admission compared to baseline. Also, FIB-4 was increased from baseline to the time of admission (1.53±0.88 vs. 2.55±1.91; p<0.001), and up to 6.9% (10/145) of patients with FIB-4<1.45 at admission died versus 47.5% if FIB-4>3.25 (58/122) (p<0.001). In the adjusted multivariate analysis, FIB-4 at admission (OR 1.14 (95%CI 1.03-1.27); p=0.015) was independently associated with mortality. Also, AST (42±38 vs. 22±17IU/L; p<0.001) and ALT (40±50 vs. 20±19 IU/L; p<0.001) were significantly reduced at 6 months after the resolution of infection. Accordingly, FIB-4 decreased significantly (2.12±1.25 vs. 1.32±0.57; p<0.001) six months after the infection. Increased FIB-4, either at baseline or at the time of admission, was related to the severity and mortality related to SARS-CoV-2 infection. However, the liver damage expressed by elevated transaminases and FIB-4 was reversible in most of patients.]]></description><issn>1130-0108</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNptkU1r3DAQhnVoaJJt_kEohkDpxZvRlyUf023TLoTm0uYqtPKoq-K1HEkbSH997WwCDZQ5zKB53gHxEHJOYUkV4_IyIXZLBkwsW03p5TTxN-SEUg41UNDH5DTn3wCCN5K9Jcdcq0aBkCfk-_X6Uy2q7GLCyuZqTNgFV2Kqoq9Wt3frzzVt64S9LdhVGR8whfJYhaHaxjyGYvvwZ1qMtgQcSn5HjrztM5499wX5ef3lx-pbfXP7db26uqkd51DqllqJHVeCcu_bVlsNiosNeqYaQCp10zG_6SRXvEXaio0DxZj0UsjWN9TxBfl4uDumeL_HXMwuZId9bweM-2w4SAVKwnRgQS4O6C_bowmDjyVZN-PmSlMmdANUT9TyP9RUHe6CiwP6ML2_Cnz4J7BF25dtjv2-hDjk16A4gC7FnBN6M6aws-nRUDBP9sxsz8z2zGxvnvgUe__8w_1mN61fQi_q-F_JcpPb</recordid><startdate>20240901</startdate><enddate>20240901</enddate><creator>Lucena Valera, Ana</creator><creator>Aller Dela Fuente, Rocío</creator><creator>Sánchez Torrijos, Yolanda</creator><creator>Romero Gómez, Manuel</creator><creator>Ampuero Herrojo, Javier</creator><general>Sociedad Espanola de Patologia Digestivas</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>INF</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8494-8947</orcidid><orcidid>https://orcid.org/0000-0003-1460-545X</orcidid><orcidid>https://orcid.org/0000-0002-8332-2122</orcidid></search><sort><creationdate>20240901</creationdate><title>FIB-4 score as predictor of COVID-19-related severity in hospitalized patients</title><author>Lucena Valera, Ana ; Aller Dela Fuente, Rocío ; Sánchez Torrijos, Yolanda ; Romero Gómez, Manuel ; Ampuero Herrojo, Javier</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c330t-91a5ed37413ff998a80734bef2760e1586d2fbd53739e194bc07225f5459f61c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; spa</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lucena Valera, Ana</creatorcontrib><creatorcontrib>Aller Dela Fuente, Rocío</creatorcontrib><creatorcontrib>Sánchez Torrijos, Yolanda</creatorcontrib><creatorcontrib>Romero Gómez, Manuel</creatorcontrib><creatorcontrib>Ampuero Herrojo, Javier</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale OneFile: Informe Academico</collection><collection>MEDLINE - Academic</collection><jtitle>Revista española de enfermedades digestivas</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lucena Valera, Ana</au><au>Aller Dela Fuente, Rocío</au><au>Sánchez Torrijos, Yolanda</au><au>Romero Gómez, Manuel</au><au>Ampuero Herrojo, Javier</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>FIB-4 score as predictor of COVID-19-related severity in hospitalized patients</atitle><jtitle>Revista española de enfermedades digestivas</jtitle><addtitle>Rev Esp Enferm Dig</addtitle><date>2024-09-01</date><risdate>2024</risdate><volume>116</volume><issue>9</issue><spage>465</spage><pages>465-</pages><issn>1130-0108</issn><abstract><![CDATA[To determine the impact of liver fibrosis on the prognosis of COVID and the liver injury associated with the infection. Retrospective multicenter study including 575 patients requiring admission for COVID-19 between January and June 2020. FIB-4 was calculated within 6 months prior to infection and at 6 months post-infection. Baseline FIB-4 was increased in patients who died (1.91±0.95 vs. 1.43±0.85; p<0.001). In addition, the 17.1% (32/187) of patients with baseline FIB-4<1.45 died versus 52.9% (9/17) if FIB-4>3.25 (p<0.001). In the adjusted multivariate analysis, baseline FIB-4 (OR 1.61 (95%CI 1.19-2.18); p=0.002) was independently associated with mortality. Parameters associated with liver injury, including AST (28±10 vs. 45±56IU/L; p<0.001) and ALT (20±12 vs. 38±48IU/L; p<0.001) were significantly higher at admission compared to baseline. Also, FIB-4 was increased from baseline to the time of admission (1.53±0.88 vs. 2.55±1.91; p<0.001), and up to 6.9% (10/145) of patients with FIB-4<1.45 at admission died versus 47.5% if FIB-4>3.25 (58/122) (p<0.001). In the adjusted multivariate analysis, FIB-4 at admission (OR 1.14 (95%CI 1.03-1.27); p=0.015) was independently associated with mortality. Also, AST (42±38 vs. 22±17IU/L; p<0.001) and ALT (40±50 vs. 20±19 IU/L; p<0.001) were significantly reduced at 6 months after the resolution of infection. Accordingly, FIB-4 decreased significantly (2.12±1.25 vs. 1.32±0.57; p<0.001) six months after the infection. Increased FIB-4, either at baseline or at the time of admission, was related to the severity and mortality related to SARS-CoV-2 infection. However, the liver damage expressed by elevated transaminases and FIB-4 was reversible in most of patients.]]></abstract><cop>Spain</cop><pub>Sociedad Espanola de Patologia Digestivas</pub><pmid>38767045</pmid><doi>10.17235/reed.2024.9811/2023</doi><orcidid>https://orcid.org/0000-0001-8494-8947</orcidid><orcidid>https://orcid.org/0000-0003-1460-545X</orcidid><orcidid>https://orcid.org/0000-0002-8332-2122</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1130-0108
ispartof Revista española de enfermedades digestivas, 2024-09, Vol.116 (9), p.465
issn 1130-0108
language eng ; spa
recordid cdi_proquest_miscellaneous_3057075037
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
title FIB-4 score as predictor of COVID-19-related severity in hospitalized patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T14%3A23%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=FIB-4%20score%20as%20predictor%20of%20COVID-19-related%20severity%20in%20hospitalized%20patients&rft.jtitle=Revista%20espa%C3%B1ola%20de%20enfermedades%20digestivas&rft.au=Lucena%20Valera,%20Ana&rft.date=2024-09-01&rft.volume=116&rft.issue=9&rft.spage=465&rft.pages=465-&rft.issn=1130-0108&rft_id=info:doi/10.17235/reed.2024.9811/2023&rft_dat=%3Cgale_proqu%3EA812486018%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3057075037&rft_id=info:pmid/38767045&rft_galeid=A812486018&rfr_iscdi=true